Targeting of CB1 and CB2 with endogenous or synthetic agonists reduced cell proliferation in vitro and in vivo and induced programmed cell death selectively in tumor cells of mantle cell lymphoma (Flygare et al., 2005; Gustafsson et al., 2006; Gustafsson et al., 2008; Wasik et al., 2011). This evidence concerns the gene CNR1 and neoplasm.